STANDARD BIOTOOLS INC. Annual Report - A Year of Transformation and Strategic Shifts (2025)

For investors in STANDARD BIOTOOLS INC. (LAB), the fiscal year ending December 31, 2025, marked a period of significant strategic transformation and financial adjustments. This report highlights the key takeaways as the company navigates a dynamic market.

Company Snapshot

STANDARD BIOTOOLS INC. trades on the Nasdaq Global Select Market. As an "accelerated filer," the company is a well-established public entity with a consistent reporting history, known for its timely SEC filings.

Business Overview

STANDARD BIOTOOLS INC. is a life sciences company that develops, manufactures, and sells innovative instruments, consumables, and software. These products support biological research and clinical applications. The company's core technologies enable high-volume analysis of complex biological systems, primarily serving academic, government, and commercial research institutions, as well as diagnostic laboratories. Its product portfolio focuses on genomics, proteomics, and single-cell analysis, advancing personalized medicine, disease research, and drug discovery.

Financial Performance: A Year of Strategic Investment (2025)

The year 2025 presented a complex financial landscape for STANDARD BIOTOOLS:

• Revenue: Total revenue reached $150 million, a decrease from $170 million in 2024. Reduced demand in specific product lines and competitive pressures, alongside strategic decisions to de-emphasize certain legacy offerings, drove this decline.
• Net Loss: The company reported a net loss of $40 million, widening from a $30 million loss in 2024. Restructuring charges and increased R&D investments significantly impacted this result.
• Earnings Per Share (EPS): Diluted EPS stood at -$1.20 for 2025.
• Operating Expenses:
  • Research & Development (R&D): Increased to $50 million (from $45 million in 2024), reflecting continued investment in innovation and new product development.
  • Selling, General & Administrative (SG&A): Decreased to $70 million (from $75 million in 2024), partly due to implemented cost-saving initiatives.
  • Cost of Sales: Remained relatively stable at $60 million.
• Cash Flow: Cash flow from operations was -$25 million, indicating the company used cash for its operations and strategic initiatives during the year. The company ended the year with $75 million in cash and equivalents.

Management's Discussion and Analysis (MD&A) Highlights

Management characterized 2025 as a year of significant strategic transformation, influencing both financial results and future positioning. The revenue decline to $150 million from $170 million stemmed from reduced demand, competitive pressures, and a strategic shift away from certain legacy products. The widening net loss of $40 million (up from $30 million) reflects these revenue challenges alongside substantial investments in the company's future.

Specifically, a $50 million increase in R&D spending underscores a commitment to innovation and new product development. Additionally, the company incurred $10 million in restructuring charges related to workforce optimization, aiming for long-term operational efficiency. The pending merger with Palamedrix represents a pivotal strategic move, designed to expand the product portfolio into high-growth proteomics and personalized medicine diagnostics. Management anticipates significant long-term benefits from this merger, despite near-term integration efforts. Cost-saving initiatives, evident in the decrease in SG&A expenses, are expected to boost profitability in future periods. The negative cash flow from operations highlights the company's investment phase, as it used cash to fund strategic initiatives and maintain operations during this transitional period.

Key Strategic Moves & Business Developments

2025 was a pivotal year for strategic realignment and portfolio expansion:

• Merger Agreement with Palamedrix: On July 2, 2025, STANDARD BIOTOOLS entered into a definitive merger agreement with Palamedrix, a leader in advanced proteomics solutions. This strategic acquisition, valued at approximately $200 million, will significantly expand STANDARD BIOTOOLS' product portfolio into high-growth areas and enhance its market position in personalized medicine diagnostics. The merger is anticipated to close in early 2026, pending regulatory approvals.
• Workforce Optimization: To streamline operations and enhance cost efficiency, the company implemented a workforce reduction plan on September 13, 2025. This plan impacted approximately 100 employees (or 15% of its workforce) across various departments. The company recognized restructuring charges and employee severance costs totaling $10 million in 2025, and expects these actions to yield annual cost savings of approximately $15 million starting in 2026.
• Share Repurchase Program: Initiated on February 6, 2024, the company's Board authorized a $50 million share repurchase program. As of December 31, 2025, the company had repurchased approximately $20 million worth of its common stock. This demonstrates confidence in its long-term value and aims to enhance shareholder returns. The program has no fixed expiration date.
• Sengenics Partnership: On November 21, 2024, STANDARD BIOTOOLS announced a strategic licensing agreement with Sengenics. This collaboration integrates Sengenics' proprietary protein array technology into STANDARD BIOTOOLS' research platforms, broadening the company's offerings in biomarker discovery and validation.
• SomaScan Business with Illumina: The company continues its important collaboration with Illumina for its SomaScan business, a critical platform for high-throughput protein analysis. This partnership remains a key revenue stream and a cornerstone of STANDARD BIOTOOLS' diagnostics and research solutions, contributing approximately $35 million in revenue in 2025.

Financial Health and Liquidity

As of December 31, 2025, STANDARD BIOTOOLS INC. reported $75 million in cash and cash equivalents. Cash flow from operations was negative $25 million for the year, reflecting ongoing investments in R&D and strategic initiatives, as well as the impact of the net loss. Existing cash reserves support the company's liquidity position, and management believes these are sufficient to fund operations and planned capital expenditures for at least the next 12 months. The share repurchase program indicates management's confidence in the company's intrinsic value and its commitment to returning capital to shareholders while managing capital structure.

Competitive Position

STANDARD BIOTOOLS operates in a highly dynamic and competitive life sciences tools and diagnostics market. The company competes based on technological innovation, product performance, data quality, customer service, and the breadth of its application offerings. Its competitive strategy involves continuous investment in research and development to introduce differentiated products, strategic partnerships like the one with Sengenics, and acquisitions such as the pending merger with Palamedrix to expand market reach and technological capabilities. The company leverages its expertise in high-throughput analysis and protein-based diagnostics to maintain and grow market share against both established industry leaders and emerging specialized firms. Facing intense pricing pressures and rapid technological advancements, STANDARD BIOTOOLS differentiates itself through integrated solutions that address complex biological questions for its diverse customer base.

Risks to Monitor

Investors should be aware of several key risks:

• Customer Concentration: A single genomics customer generated approximately 25% of STANDARD BIOTOOLS' 2025 revenue. Reliance on a limited number of customers poses a risk if that relationship changes or orders decrease.
• Geographic Concentration: The company faces notable geographic concentration risk, with approximately 30% of its 2025 revenue originating from China. Political, economic, or regulatory changes in this region could materially impact sales and operations.
• Integration Risk: The pending merger with Palamedrix introduces integration risks, including potential challenges in combining operations, retaining key personnel, and achieving anticipated synergies. Failure to successfully integrate could negatively impact financial performance.
• Competitive Landscape: The life sciences tools and diagnostics market is highly competitive, characterized by rapid technological advancements and intense pricing pressures from established players and new entrants.
• Regulatory Environment: The company operates in a highly regulated industry. Changes in regulatory policies or increased scrutiny could impact product development, approval, and commercialization.

Outlook for 2026

STANDARD BIOTOOLS is actively positioning itself for future growth through strategic acquisitions and operational efficiencies. While 2025 saw a decline in revenue and increased losses due to strategic investments and restructuring, the company anticipates the Palamedrix merger and cost-saving measures will contribute to improved financial performance and expanded market reach in 2026 and beyond. Investors should closely monitor the successful integration of Palamedrix and the realization of expected synergies.